David is a partner at Lux. He has a passion for entrepreneurs and innovators in therapeutics, R&D tools, and biopharma infrastructure. His passion for biotech first started at the Broad Institute, where he developed computational and experimental tools for viral diagnostics, with results published in Nature and Cell.

He is a generalist at Lux, which has $7 billion under management, and has been first investors in category-defining companies across AI, automation, biotech, compute, defense, energy, infrastructure, robotics, and beyond — including Anduril, Applied Intuition, Auris, Chronosphere, Cognition, Eikon, Hugging Face, Impulse Space, Physical Intelligence, Runway, Sakana, and Together.  Lux has created and co-founded more than 20 de novo companies through Lux Labs, and multiple Lux investments have become lasting publicly traded companies and major divisions acquired by Amazon, Cisco, Databricks, J&J, Meta, Palo Alto Networks, and more. 

David was the co-founder and Head of Strategy & Ops of Latus Bio, a gene therapy company focused on neurological disorders, before becoming an investor in therapeutics and life sciences infrastructure companies. He is a graduate of Harvard University.